Michael Yu

Biography

  "Co-founder,Chairman, President & CEO of Innovent Biologics.With a doctoral degree in Molecular Genetics from the Chinese Academy of Sciences and postdoctoral training in Pharmaceutical Chemistry from the University of California at San Francisco (UCSF), Dr. Michael Yu has been designated as a distinguished expert in China’s “Thousand Talents Program” and is distinguished as the only person in China who has invented and commercialized two Class One novel drugs in China (Oncorine® and Conbercept®). Oncorine was the first oncolytic drug developed by genomic engineering, which set China as the first country in the world to approve  an immune-oncolytic therapy.  The US FDA approved a same class drug in 2015, ten years after Oncorine’s China approval.  Conbercept is the first innovative drug invented in China that was officially named by the World Health Organization. In November, 2016, the US FDA approved Conbercept to start phase III directly in US without first requiring Phase I studies, making it the first China originated drug to have this distinction. "     

Research Interest

   BIOSCIENCES